Healthcare / Medical DevicesUpdated 2026-05-10 22:07 UTC

HAE stock hub

Haemonetics Corporation has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

HAEis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

2.6B

NYSE

Market data

Live price

Current market quote for this ticker.

Current price

HAE

In the news

Latest news · HAE

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E10.5

P25 12.3P50 18.4P75 33.1

Trailing P/E26.9

P25 14.9P50 23.2P75 38.5

ROE12

P25 -105.6P50 -46.5P75 -3.1

ROIC10.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All HAE market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

264

Groups with data

Currency

USD

Showing 264 of 264 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000313143
Company name	Haemonetics Corporation
Country	United States
Country code	US
Cusip	405024100
Employees	3,023
Employees Change	-634%
Employees Change Percent	-17.34
Enterprise value	$3.5B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
Industry	Medical Devices
IPO Date	1991-05-09
Isin	US4050241003
Last refreshed	2026-05-10
Market cap	$2.6B
Market cap category	Mid-Cap
Price	$55.12
Price currency	USD
Rev Per Employee	441,292.42x
Sector	Healthcare
Sic	3841
Symbol	HAE
Website	https://www.haemonetics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.8%
EV Earnings	36.39x
EV Sales Forward	2.52x
EV/EBIT	14.14x
EV/EBITDA	9.78x
EV/FCF	13.59x
EV/Sales	2.65x
FCF yield	10.17%
Forward P/E	10.51x
P/B ratio	3.2x
P/E ratio	26.89x
P/S ratio	1.92x
PE Ratio10 Y	93.23x
PE Ratio3 Y	28.28x
PE Ratio5 Y	43.89x
PEG ratio	1.11x
PS Forward	1.83x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	18.77%
EBITDA Margin	27.14%
FCF margin	19.52%
Gross margin	59.71%
Gross Profit	$796.6M
Gross Profit Growth	2.32%
Gross Profit Growth Q	0.06%
Gross Profit Growth3 Y	8.55%
Gross Profit Growth5 Y	13.21%
Net Income	$97.3M
Net Income Growth	-41.97%
Net Income Growth Quarters	2%
Net Income Growth Years	3%
Net Income Growth3 Y	-5.53%
Net Income Growth5 Y	4.13%
Pretax Margin	9.6%
Profit Margin	7.29%
Profit Per Employee	$32,189
Profitable Years	8
ROA	6.46
Roa5y	5.69
ROCE	11.85
ROE	12.03
Roe5y	12.93
ROIC	10.73
Roic5y	9.63

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	7.09%
Cagr15y	3.35%
Cagr1y	-14.22%
Cagr20y	3.73%
Cagr3y	-12.49%
Cagr5y	-2.02%
EPS Growth	-38.07
EPS Growth Quarters	2
EPS Growth Years	3
EPS Growth3 Y	-2.91
EPS Growth5 Y	5.75
FCF Growth	82.83%
FCF Growth Q	-47.2%
FCF Growth3 Y	47.15%
FCF Growth5 Y	29.41%
OCF Growth	61.35%
OCF Growth Q	-39.14%
OCF Growth10 Y	9.18%
OCF Growth3 Y	2.4%
OCF Growth5 Y	21.93%
Revenue Growth	-1.97x
Revenue Growth Q	4.77x
Revenue Growth Years	4x
Revenue Growth3 Y	4.51x
Revenue Growth5 Y	8.91x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.55
Assets	$2.4B
Cash	$245.4M
Current Assets	$834.9M
Current Liabilities	$282.6M
Debt	$1.2B
Debt EBITDA	$3.38
Debt Equity	$1.54
Debt FCF	$4.7
Equity	$796.3M
Interest Coverage	9.49
Liabilities	$1.6B
Long Term Assets	$1.6B
Long Term Liabilities	$1.3B
Net Cash	$-979.1M
Net Cash By Market Cap	$-38.23
Net Debt EBITDA	$2.7
Net Debt Equity	$1.23
Net Debt FCF	$3.76
Tangible Book Value	$-307.7M
Tangible Book Value Per Share	$-6.66
WACC	5.37

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.95
Inventory Turnover	1.6
Net Working Capital	$311.9M
Quick ratio	1.64
Working Capital	$552.3M
Working Capital Turnover	$2.93

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	6.65%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	98.27%
1Y total return	-14.21%
200-day SMA	63.06
3Y total return	-32.98%
50-day SMA	59.31
50-day SMA vs 200-day SMA	50under200
5Y total return	-9.7%
All Time High	142.1
All Time High Change	-61.21%
All Time High Date	2021-02-09
All Time Low	5.78
All Time Low Change	853.47%
All Time Low Date	1991-05-10
ATR	2.77
Beta	0.53
Beta1y	0.26
Beta2y	0.58
Ch YTD	-31.23
High	56.11
High52	87.32
High52 Date	2025-12-10
High52ch	-36.88%
Low	51
Low52	47.32
Low52 Date	2025-09-26
Low52ch	16.5%
Ma50ch	-7.06%
Premarket Change Percent	1.69
Premarket Price	$55.29
Premarket Volume	18,784
Price vs 200-day SMA	-12.59%
RSI	40.44
RSI Monthly	42.83
RSI Weekly	40.01
Sharpe ratio	-0.12x
Sortino ratio	-0.06
Total Return	6.65%
Tr YTD	-31.23
Tr15y	63.9%
Tr1m	-7.45%
Tr1w	-6.99%
Tr3m	-7.11%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	10
Analyst Ratings	Buy
Earnings EPS Estimate	$1.27
Earnings EPS Estimate Growth	2.42
Earnings Revenue Estimate	337,119,712x
Earnings Revenue Estimate Growth	1.97x
Operating Income	$250.4M
Operating Income Growth	1.33
Operating Income Growth Q	-7.66
Operating Income Growth3 Y	14.41
Operating Income Growth5 Y	20.13
Operating margin	18.77
Price target	$81.67
Price Target Change	$48.17

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	45,927,993%
Float Percent	98.83%
Net Borrowing	-6,250,000
Shares Insiders	1.13%
Shares Institutions	102.02%
Shares Out	46,471,350
Shares Qo Q	-1.62%
Shares Yo Y	-6.66%
Short Float	4.34%
Short Ratio	2.96
Short Shares	4.29

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$226.6M
Average Volume	766,197.05x
Bv Per Share	17.23
CAPEX	$-32.8M
Ch10y	98.27
Ch15y	63.9
Ch1m	-7.45
Ch1w	-6.99
Ch1y	-14.21
Ch20y	108
Ch3m	-7.11
Ch3y	-32.98
Ch5y	-9.7
Ch6m	-19.37
Change	1.38%
Change From Open	2.72
Close	54.37
Days Gap	-1.31
Depreciation Amortization	111,717,000
Dollar Volume	61,858,805.8
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$250.4M
EBITDA	$362.1M
EPS	$2.05
F Score	6
FCF	$260.4M
FCF EV Yield	7.36x
FCF Per Share	$5.6
Financing CF	-178,460,000
Fiscal Year End	March
Founded	1,971
Goodwill	656,368,000
Graham Number	28.18891
Graham Upside	-48.86
Income Tax	$30.7M
Investing CF	-179,547,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-28
Last Split Date	2012-12-03
Last Split Type	Forward
Last10k Filing Date	2025-05-21
Lynch Fair Value	$10.25
Lynch Upside	-81.4
Ma150	65.06
Ma150ch	-15.28%
Ma20	58.86
Ma20ch	-6.36%
Net CF	-61,323,000
Next Earnings Date	2026-08-06
Open	53.66
Optionable	Yes
P FCF Ratio	9.84
P OCF Ratio	8.74
Position In Range	80.63
Post Close	55.12
Postmarket Change Percent	-1.31
Postmarket Price	$54.4
Ppne	305,761,000
Pre Close	54.37
Price Date	2026-05-08
Price EBITDA	$7.07
Relative Volume	1.46x
Revenue	1,334,027,000x
SBC By Revenue	2.54x
Share Based Comp	33,827,000
Tax By Revenue	2.3x
Tax Rate	24%
Tr20y	107.96%
Tr6m	-19.37%
Us State	Massachusetts
Volume	1,122,257

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does HAE pay a dividend?

Capital-return profile for this ticker.

Performance

HAE stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns HAE?

Insider, institutional, and short-interest positioning.

Institutional ownership

+102.0%

Float: +98.8% of shares outstanding

Insider ownership

+1.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

HAE momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

40.4

Neutral momentum band

Price vs 200-day MA

-12.6%

50/200-day relationship not available

Beta (5Y)

0.53

Less volatile than the market

Sharpe ratio

-0.12

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About HAE

Hub-level FAQ points readers to the deeper analysis pages.

What is the current HAE stock rating?

Haemonetics Corporation is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full HAE analysis?

The full report lives at /stocks/HAE/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for HAE?

The latest report frames HAE around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the HAE page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.